Can I take CBD if I'm on methotrexate?

Talk to your rheumatologist first. The mechanism (CBD inhibits CYP3A4, which partially metabolizes MTX) is plausible, but the MTX-CBD interaction hasn't been quantified in a clinical trial. The strongest evidence is Bansal 2023, an n=18 RCT showing CBD raised CYP3A substrate plasma exposure 56–207%. Reclaim does not recommend stopping or adjusting methotrexate.

Is the topical roll-on or transdermal patch safer with methotrexate than the oil?

Possibly — at least from a CYP-exposure perspective. Oral CBD has the highest first-pass through the liver and therefore the largest CYP impact. Topical CBD has minimal systemic absorption. Transdermal patches deliver CBD systemically but at lower peak concentrations than oral. If your rheumatologist supports a CBD trial, the lower-systemic-exposure formats reduce the CYP-pathway concern.

What about CBD and MTX side effects? Can it help with the nausea?

There's no clinical trial of CBD for MTX-induced nausea. CBD has antiemetic mechanisms in other contexts and customer reports of GI relief on CBD are common, but we cannot recommend CBD as a treatment for MTX side effects. If MTX side effects are unmanageable, the priority conversation is with your rheumatologist about MTX dose, timing, or folate; CBD is downstream of that.

I take MTX once a week. Does the timing of CBD relative to MTX matter?

Possibly. CBD's CYP inhibition outlasts its plasma half-life — the enzyme inhibition can persist for hours. If you take MTX once weekly, the CYP3A4 pathway is most relevant on the day of MTX administration; daily CBD use means CYP3A4 is partially inhibited every day. Whether to time CBD differently around MTX administration is a question for your rheumatologist.

Will my rheumatologist know about this?

Maybe, maybe not. A 2018 Arthritis Foundation survey found 58% of patients who told their doctor about CBD use did not get the safety, dosing, or interaction information they were looking for. Many rheumatologists are under-informed because CBD-Rx interaction research is recent. Bring this page to your appointment.

CBD and methotrexate: what to know about interactions

MTX is metabolized partly by CYP3A4, which CBD inhibits.

Bansal 2023 (n=18 RCT) showed CBD raised CYP3A substrate exposure 56–207% at research doses.

An MTX-specific CBD interaction RCT does not exist; the mechanism is plausible but unquantified for MTX.

Do not stop or adjust methotrexate. Talk to your rheumatologist about timing and folate monitoring if you choose to combine.

The roll-on (topical) and patches (transdermal) have lower systemic CBD exposure than the oil — discuss format with your prescriber.

What the science says

The CYP3A4 pathway evidence

Bansal 2023 is the strongest direct clinical evidence: a randomized, double-blind, placebo-controlled trial in 18 healthy adults found CBD-dominant cannabis raised CYP3A substrate plasma exposure by 56–207%. The mechanism — competitive inhibition of CYP3A4 by CBD — was confirmed in vitro by Yamaori 2011 at clinically achievable concentrations.

The breadth

Stöllberger 2023 reviewed 403 CYP-substrate drugs and concluded CBD has pathway overlap with 67–68% of frequently prescribed medications. Methotrexate is on that list: MTX undergoes CYP3A4-mediated 7-hydroxylation as a minor metabolic pathway alongside its primary UGT glucuronidation and renal elimination.

MTX-specific evidence — the honest gap

There is no MTX-CBD interaction RCT. The closest published parallels are case reports of CBD elevating other autoimmune-relevant immunosuppressants — Cuñetti 2024 documented CBD-induced rises in cyclosporine and mycophenolate plasma levels in a kidney transplant patient. Nachnani 2024's 31-report systematic review similarly catalogs tacrolimus, sirolimus, and warfarin interactions but no MTX-specific case.

What this adds up to

The mechanism is plausible (shared CYP3A4 pathway). The magnitude for MTX specifically isn't quantified. At wellness-CBD doses (25–50mg/day), CYP exposure is lower than in the Bansal trial (~750mg/day equivalent) but not zero. Pharmacogenomic variation matters — different patients have different CYP3A4 activity baselines, so the same dose has different effects in different people.

The mechanism

MTX metabolism is multi-pathway. Roughly 80% of an MTX dose is eliminated unchanged by the kidneys; the remaining ~20% is hepatically processed. Hepatic processing includes CYP3A4-mediated 7-hydroxylation (minor), UGT1A glucuronidation, aldehyde oxidase oxidation, and folate-pathway interaction.

CBD inhibits CYP3A4 competitively — the inhibition is dose-dependent and persists for hours beyond CBD's plasma half-life. CBD also affects UGT1A enzymes, which contribute to MTX glucuronidation; the specific MTX-UGT-CBD interaction has not been quantified clinically.

Because MTX has parallel elimination pathways, partial inhibition of any one shifts the load to the others. The clinical impact depends on which pathway dominates in you — which depends on your kidney function, your folate status, and your CYP3A4 baseline. There is no single magnitude that applies to every patient. See the CYP450 mechanism explainer for the foundational pharmacology.

What this means for you

Talk to your rheumatologist before starting CBD. Bring this page if helpful. The CYP3A4 + UGT framing helps the conversation move from "I don't know" to specifics.
Folate monitoring. MTX therapy requires folate supplementation. CBD's effect on the folate pathway hasn't been studied; if you're already on folate, your rheumatologist may want to monitor levels more closely after CBD initiation.
CBC + LFT monitoring. Standard MTX monitoring (CBC and liver function tests every 8–12 weeks per ACR guidelines) becomes especially important when CBD is added. CBD can elevate liver enzymes at high doses; combined with MTX hepatotoxicity, this is a meaningful flag.
Format choice. Oral CBD has the highest first-pass through the liver, and therefore the largest CYP impact. Topical CBD (the Reclaim NANO roll-on) has minimal systemic absorption. Transdermal patches (the 50mg patches) deliver CBD systemically but bypass first-pass. If you choose to combine, your rheumatologist may prefer the lower-systemic-exposure format.
Dose conservatism. If you and your rheumatologist agree to try CBD, start at the low end (10–25mg) and titrate slowly. See our titration protocol for the ramp.
Don't change MTX without your rheumatologist. Reclaim does not recommend stopping or reducing MTX based on CBD use.
Other autoimmune-stack interactions. If you also take a biologic, prednisone, or hydroxychloroquine, see the per-medication pages for each.

Methotrexate brand names

Brand name	Generic	Form
Rheumatrex	Methotrexate	Oral tablet
Trexall	Methotrexate	Oral tablet
Otrexup	Methotrexate	Subcutaneous auto-injector
Rasuvo	Methotrexate	Subcutaneous injection

Subcutaneous MTX (Otrexup, Rasuvo) bypasses first-pass metabolism somewhat, which slightly changes the metabolic profile. This page applies to both routes; the CYP3A4 + UGT involvement remains.

CBD and methotrexate: a research-led safety overview

Key takeaways